O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

Background: Patients with HIV RNA suppression below 50 copies/mL may still have HIV RNA detectable by more sensitive PCR assay techniques. Methods: In the MONET trial, 256 patients with HIV RNA 1000: 4%) and 47/1051 samples in the DRV/r + 2NRTI arm (50-400: 83%, 400-1000: 8.5%, >1000: 8.5%). Conclusions: In this study for patients with HIV RNA <50 copies/mL at baseline, switching to DRV/r monotherapy showed similar levels of HIV RNA suppression to DRV/r + 2NRTIs, using more sensitive PCR assay techniques. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-O19 Cite this article as: Clumeck et al.: O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial. Journal of the International AIDS Society 2010 13(Suppl 4):O19. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112831/